

Pathological Lying: Symptom or Disease?

Lying With No Apparent Motive or Benefit

by Charles C. Dike, MD, MPH, MRCPsych

Pathological lying (PL) is a controversial topic. There is, as yet, no consensus in the psychiatric community on its definition, although there is general agreement on its core elements. PL is characterized by a long history (maybe lifelong) of frequent and repeated lying for which no apparent psychological motive or external benefit can be discerned. While ordinary lies are goal-directed and are told to obtain external benefit or to avoid punishment, pathological lies often appear purposeless. In some cases, they might be self-incriminating or damaging, which makes the behavior even more incomprehensible.

CHECK POINTS

- ✓ Pathological lying (PL) is noted for the chronicity and frequency of the lies and the apparent lack of benefit derived from them.
- ✓ Pathological liars believe their lies to the extent that the belief may be delusional.
- ✓ Lying behaviors that mimic PL have been described in certain personality disorders and in factitious disorder.
- ✓ Conditions that could be confused with PL include malingering, Ganser syndrome, and confabulation.

Despite its relative obscurity, PL has been recognized and written about in the psychiatric literature for more than a century. The German physician, Anton Delbruck,¹ is credited with being the first to describe the concept of PL. He observed that some of his patients told lies that were so abnormal and out of proportion that they deserved a special category. He subsequently described the lies as “pseudologia phantastica.”

CASE VIGNETTE

Mr A was desperate. He was about to lose yet another job, not because he was at risk for being fired, but because his lying behavior had finally boxed him into a corner.

He had lied repeatedly to his colleagues, telling them that he had an incurable disease and was receiving palliative treat-

ment. Initially, his coworkers treated him with sensitivity and concern, but as the weeks wore on, the scrutiny of his col-

leagues became increasingly pointed. He had to tell more and more outrageous lies

(Please see Pathological Lying, page 68)

SEROQUEL stabilizes mood in bipolar disorder and is the only atypical proven effective in both acute mania AND bipolar depression^{1,2}



Important Safety Information

- SEROQUEL is indicated for the treatment of depressive episodes in bipolar disorder; acute manic episodes in bipolar I disorder, as either monotherapy or adjunct therapy to lithium or divalproex; and schizophrenia. Patients should be periodically reassessed to determine the need for treatment beyond the acute response
- Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk (1.6 to 1.7 times) of death, compared to placebo (4.5% vs 2.6%, respectively). SEROQUEL is not approved for the treatment of patients with dementia-related psychosis (see Boxed Warning)
- Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies of major depressive disorder and other psychiatric disorders. Patients of all ages started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. SEROQUEL is not approved for use in patients under the age of 18 years (see Boxed Warning)

Please see additional Important Safety Information on following pages, and Brief Summary of Prescribing Information, including Boxed Warnings, at the end of this ad.

 **Seroquel**[®]
quetiapine fumarate
25 mg, 50 mg, 100 mg, 200 mg, 300 mg & 400 mg tablets

Pathological Lying

Continued from page 67

to cover his tracks and justify having a terminal illness. Finally, when the heat became too unbearable, he suddenly stopped going to work. On the face of it, it would seem Mr A told these lies to gain the sympathy of his colleagues, but the consequences of his lying, in terms of emotional distress and potential loss of job, far outweighed any perceived gain.

Mr A had lost several other jobs in the past because of his lying, and he was becoming frustrated. Family members reported that he often told blatant lies, and even when confronted, and proved wrong, he still swore they were true. Mr A finally sought psychiatric help after concluding that he could not stop himself from lying.

This scenario, or similar stories, is not uncommon in clinical practice. Letters I have received from mental

health professionals, attorneys, and individuals around the world describe similar characteristics in people they know—excessive lying, easily verifiable to be untrue, mostly unhelpful to the liar in any apparent way, and even possibly harmful to the liar, yet told repeatedly over time. Even prominent and successful individuals are not immune to this behavior—for example, the well-known California case of Judge Patrick Couwenberg, who was

removed from office not only for lying in his official capacity but also for lying under oath to a commission investigating his behavior.² A psychiatric expert witness diagnosed pseudologia phantastica and suggested that the judge needed treatment. Why such a successful individual would repeatedly tell lies that could damage his credibility and put him in trouble with the law or other administrative bodies is baffling. Was his lying

Help your patients with bipolar disorder

SEROQUEL has

- Mood-stabilizing properties²
- Proven efficacy to treat both bipolar depression and acute mania^{*†‡3-7}
- A target dose of 300 mg/day by Day 4 for bipolar depression with **once-daily dosing at bedtime**, and a target dose of 600 mg/day[†] by Day 5 in bipolar mania with **BID[§] dosing**^{2,6}

Important Safety Information (continued)

- A potentially fatal symptom complex, sometimes referred to as Neuroleptic Malignant Syndrome (NMS), has been reported in association with administration of antipsychotic drugs, including SEROQUEL. Rare cases of NMS have been reported with SEROQUEL. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. The management of NMS should include immediate discontinuation of antipsychotic drugs
- Tardive dyskinesia (TD), a potentially irreversible syndrome of involuntary dyskinetic movements, may develop in patients treated with antipsychotic drugs. The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and total cumulative dose of antipsychotic drugs administered to the patient increase. TD may remit, partially or completely, if antipsychotic treatment is withdrawn. SEROQUEL should be prescribed in a manner that is most likely to minimize the occurrence of TD
- Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma, or death, has been reported in patients treated with atypical antipsychotics, including SEROQUEL. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatment-emergent, hyperglycemia-related adverse events in patients treated with atypical antipsychotics. Patients starting treatment with atypical antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing
- Leukopenia, neutropenia, and agranulocytosis (including fatal cases), have been reported temporally related to atypical antipsychotics, including SEROQUEL. Patients with a pre-existing low white blood cell (WBC) count or a history of drug induced leukopenia/neutropenia should have their complete blood count monitored frequently during the first few months of therapy. In these patients, SEROQUEL should be discontinued at the first sign of a decline in WBC absent other causative factors. Patients with neutropenia should be carefully monitored, and SEROQUEL should be discontinued in any patient if the absolute neutrophil count is < 1000/mm³
- Precautions include the risk of seizures, orthostatic hypotension, and cataracts. Examination of the lens by methods adequate to detect cataract formation, such as slit lamp exam or other appropriately sensitive methods, is recommended at initiation of treatment, or shortly thereafter, and at 6-month intervals during chronic treatment

Please see additional Important Safety Information on adjacent pages, and Brief Summary of Prescribing Information, including Boxed Warnings, at the end of this ad.

behavior completely within his control, or was there something different about his pattern of lies?

Lying is a common human trait defined by *Merriam-Webster's Collegiate Dictionary* as making "an untrue statement with intent to deceive." Selling³ agreed, with an observation that "everyone lies and you can't stop them," and concluded, "of course, that is the truth."

PL is commonly referred to as

pseudologia phantastica (or pseudologia fantastica) and, less commonly, as mythomania, or morbid lying. It is not yet clear whether these different names refer to the same phenomenon, but they are often used interchangeably. Throughout this article, PL and pseudologia phantastica will be used synonymously.

Over the years, very little has been written on the epidemiology of PL. Although its prevalence in the general

population is unknown, one study of 1000 repeat juvenile offenders found a prevalence of close to 1%.¹ A review of 72 cases reported that the average age at onset of the lying behavior was 16 and the average age at discovery was 22.⁴ The same review showed the sex ratio to be equal; the intelligence quotient (IQ) to be average or slightly below average, with significantly better verbal IQ than performance IQ; and a history of CNS abnormality in

40% of the cases, characterized by epilepsy, abnormal electroencephalographic findings, head trauma, or CNS infection.

PL is noted for the chronicity and frequency of the lies, and the apparent lack of benefit derived from them. The lies are easily disprovable tales that are often fantastic in nature and may be extensive, elaborate, and complicated. There often appears to be a blurring

(Please see Pathological Lying, page 70)



Important Safety Information (continued)

- The most commonly observed adverse events associated with the use of SEROQUEL monotherapy versus placebo in clinical trials for schizophrenia and bipolar disorder were dry mouth (9%-44% vs 3%-13%), sedation (30% vs 8%), somnolence (18%-28% vs 7%-8%), dizziness (11%-18% vs 5%-7%), constipation (8%-10% vs 3%-4%), SGPT increase (5% vs 1%), dyspepsia (5%-7% vs 1%-4%), lethargy (5% vs 2%), and weight gain (5% vs 1%). The most commonly observed adverse events associated with the use of SEROQUEL versus placebo in clinical trials as adjunct therapy with lithium or divalproex in bipolar mania were somnolence (34% vs 9%), dry mouth (19% vs 3%), asthenia (10% vs 4%), constipation (10% vs 5%), abdominal pain (7% vs 3%), postural hypotension (7% vs 2%), pharyngitis (6% vs 3%), and weight gain (6% vs 3%)
- In long-term clinical trials of quetiapine, hyperglycemia (fasting glucose ≥ 126 mg/dL) was observed in 10.7% of patients receiving quetiapine (mean exposure 213 days) vs 4.6% in patients receiving placebo (mean exposure 152 days)

* Data combined from two 8-week, multicenter, randomized, double-blind, placebo-controlled, monotherapy bipolar depression trials. SEROQUEL (300 mg/day; n=327) showed significant improvement from baseline in Montgomery-Asberg Depression Rating Scale total score at Week 1 continuing through Week 8 vs placebo (n=330; P values ≤ 0.0001).⁵

† Data combined from two 12-week, multicenter, randomized, double-blind, placebo-controlled, monotherapy mania trials. SEROQUEL (n=208) showed significant improvement from baseline in Young Mania Rating Scale (YMRS) total score at Day 4 continuing through Day 84 vs placebo (n=195; P values ≤ 0.05).⁶

‡ In pivotal mania trials, the average dose in responders (patients with $\geq 50\%$ improvement in YMRS total score) was 600 mg/day.

§ Twice daily.

References: 1. Data on file, AstraZeneca Pharmaceuticals LP, DA-SER-51. 2. Prescribing Information for SEROQUEL. 3. Calabrese JR, Keck PE, Macfadden W, et al. *Am J Psychiatry*. 2005;162:1351-1360. 4. Thase ME, Macfadden W, Weisler RH, et al, for the BOLDER II Study Group. *J Clin Psychopharmacol*. 2006;26:600-609. 5. Endicott J, Rajagopalan K, Minkwitz M, et al, for the BOLDER Study Group. *Int Clin Psychopharmacol*. 2007;22:29-37. 6. Vieta E, Mullen J, Brecher M, et al. *Curr Med Res Opin*. 2005;21:923-934. 7. Sachs G, Chengappa KNR, Suppes T, et al. *Bipolar Disord*. 2004;6:213-223. 8. Data on file, AstraZeneca Pharmaceuticals LP, DA-SER-45.

PL often function well in many spheres of daily living.

Although the cause of PL is unknown, there are increasing associations with CNS dysfunction. As noted earlier, 40% of 72 individuals with pseudologia phantastica had a history of CNS abnormalities.⁴ In another study, single photon emission CT showed right hemithalamic dysfunction in a patient with pseudologia phantastica.¹¹

The most recent study involved the use of structural MRI in 12 individuals identified as "liars."¹² The liars group comprised 4 subgroups: malingering group, PL group (PL was defined using the Hare Psychopathy Checklist-Revised), individuals with conning/manipulative behavior, and individuals who met the deceitfulness criteria for *DSM-IV*. The study found a 22% to 26% increase in the prefrontal white matter and a 36% to 42% reduction in prefrontal gray-to-white ratios in the liars group compared with anti-social controls and normal controls. The main flaw of this study was that although half of the liars group had a diagnosis of malingering and only a small number had PL, the liars group was frequently interchanged with the pathological liars as if they were the same. In addition, PL was defined using the Hare Psychopathy Checklist, an indication that the few pathological liars included in the study were those with criminal behavior and psychopathy. To ascribe observations from this study to PL is therefore problematic and misleading; PL and malingering are different entities, and most pathological liars are not psychopaths.

There is no specific psychological test for PL. However, psychological tests would help in elucidating the presence of personality disorders, other major psychiatric illnesses, or malingering.

PL has been at the fringes of psychiatric practice for more than a century. It is not surprising, therefore, that it remains ill understood and poorly researched. The increasing interest in the phenomenon in recent years, and the availability of high-tech radiological investigations may reverse this trend and help answer the many questions that have dogged this phenomenon. Despite the fact that psychiatrists are slowly converging on a uniform definition of PL, it remains unclear whether it is a mental disorder or merely behavioral excess. Associated questions involve the treatability of the phenomenon, available treatment modalities, and outcome of treatment. A psychiatrist representing Judge Couwenberg's defense team opined that pseudologia phantastica was

treatable with therapy but did not state the basis for his assertion.

Treatment

The options available for treating PL have been poorly researched. The treatment modality mainly discussed in the literature is psychotherapy. However, there are no systematic studies on the effectiveness of psychotherapy in treating PL and no discussion of pharmacotherapy or any other types of interventions. It is possible that there may be a subset of pathological liars for whom pharmacotherapeutic options may help in reducing impulsivity or the compulsions associated with the urge to lie. In addition, further investigation of CNS abnormalities may lead to other therapeutic interventions.

To fully embark on an exploration of treatment options for PL, however, it should first be recognized as a diagnostic entity. PL currently exists as a common but unessential symptom of factitious disorder. As in other medical or psychiatric conditions, emphasis is usually on the treatment of the condition as a whole and not necessarily the treatment of its individual symptoms. Therefore, PL should be recognized as a diagnostic entity to encourage research into its treatment.

The possible consequences of PL for the liar are severe. All relationships of the liar are at risk for destruction resulting from lack of trust and credibility. The shame of socially or formally interacting with others in the company of a spouse who lies repeatedly could overwhelm the relationship. In the workplace, as their lying behavior becomes increasingly clear to their colleagues, pathological liars stand the risk of bearing the brunt of rude jokes, being alienated, or being fired. In clinical situations, the therapist has the arduous task of overcoming not only the negative countertransference of treating a habitual liar but also the frustrations of not knowing which of the patient's statements are true.

Although most individuals affected with PL may not have cause to seek treatment and may indeed continue to lead highly successful and productive lives, it is not uncommon for their lies to cause them hardship through clashes with the law or other authorities, with resulting adverse consequences. For example, a purposeless false accusation, a recognized presentation of PL, is a criminal behavior for which the pathological liar may be prosecuted. This type of false accusation should be differentiated from false accusations for revenge purposes, or those that may occur in mass hysteria (for example, the Salem witchcraft phenomenon), in which a false idea generates intense anxiety that quickly

spreads and may lead to baseless accusations.

Forensic issues

It is perhaps in the forensic psychiatric arena that the need to clearly define PL is most urgent. The immediate question in these settings would revolve around the issue of competency of the pathological liar to stand trial. The criteria for being competent to stand trial include an ability to work collaboratively with one's attorney in order to confront one's accusers. A defendant who lies frequently and repeatedly to his attorney would ultimately confuse the attorney, making it difficult to formulate a sound strategy of defense.

Another problem is the risk of the pathological liar being accused of perjury when he gives false testimony under oath. In the case of Judge Couwenberg, the State of California Commission of Judicial Performance noted that he did not have a mental condition that excused or mitigated his behavior. The commission concluded that the mere presence of a symptom without any mental disorder is of little legal consequence.

It is easier to argue that PL is not a delusion than it is to say that pathological liars always have control over their lies. Koppen¹³ observed that the lie ultimately wins power over the pathological liar, so that mastery of his own lies is lost. In addition, PL has a compulsive or impulsive quality. Would it be feasible to say that in some cases the lying behavior was uncontrollable? Such a conclusion, when combined with recent evidence of possible CNS abnormalities in PL, would raise doubts about the degree of responsibility of pathological liars when their lies lead to criminal behavior.

Conclusion

In conclusion, PL is a special form of lying, narrow in its definition and complicated in its presentation. Its apparent rarity may be the consequence of lack of awareness of the phenomenon by clinicians. Unfortunately, it periodically causes significant hardship to the pathological liar. Psychiatrists confronted with pathological liars should complete a thorough clinical evaluation and obtain a longitudinal history of their lies, especially through collateral information from relatives, friends, and employers. In addition to psychotherapeutic treatment, psychiatrists should consider research into the usefulness of pharmacotherapy for impulsivity or compulsive behaviors in these patients.

Dr Dike is division medical director at Whiting Forensic Services at the Connecticut Valley

Hospital in Middletown, and assistant clinical professor in the division of law and psychiatry of the department of psychiatry at Yale University School of Medicine in New Haven, Conn. He reports that he has no conflicts of interest concerning the subject matter of this article.

References

1. Healy W, Healy MT. *Pathological Lying, Accusation, and Swindling: A Study in Forensic Psychology*. Boston: Little, Brown, and Co; 1915. <http://books.google.com/>. Accessed May 19, 2008.
2. State of California, Before the Commission on Judicial Performance. Decision and Order Removing Judge Couwenberg from Office, August 15, 2001. <http://cjp.ca.gov/CN%20Removals/Couwenberg%208-15-01.pdf>. Accessed: May 19, 2008.
3. Selling LS. The psychiatric aspects of the pathological liar. *Nerv Child*. 1942;1:335-350.
4. King BH, Ford CV. Pseudologia fantastica. *Acta Psychiatr Scand*. 1988;77:1-6.
5. Deutsch H. On the pathological lie (pseudologia phantastica). *J Am Acad Psychoanal*. 1982;10:369-386.
6. Wiersma D. On pathological lying. *Character Pers*. 1933;2:48-61.
7. Powell GE, Gudjonsson GH, Mullen P. Application of guilty-knowledge technique in a case of pseudologia fantastica. *Pers Individ Dif*. 1983;4:141-146.
8. Cleckley H. *The Mask of Sanity*. 3rd ed. St Louis: Mosby; 1955.
9. Dike CC, Baranoski M, Griffith EE. Pathological lying revisited. *J Am Acad Psychiatry Law*. 2005;33:342-349.
10. Fenichel O. The economics of pseudologia phantastica. In: Fenichel H, Rapaport D, eds. *The Collected Papers of Otto Fenichel, Second Series*. New York: WW Norton and Co; 1954:129-140.
11. Modell JG, Mountz JM, Ford CV. Pathological lying associated with thalamic dysfunction demonstrated by [99mTc] HMPAO SPECT. *J Neuropsychiatry Clin Neurosci*. 1992;4:442-446.
12. Yang Y, Raine A, Lencz T, et al. Prefrontal white matter in pathological liars. *Br J Psychiatry*. 2005;187:320-325.
13. Koppen M. Ueber die pathologische Lüge (Pseudologia phantastica). *Charite-Annalen*. 1898;8:674-719. Gault RH, Crossley FB, Garner JW, eds. In: *Pathological Lying, Accusation, and Swindling: A Study in Forensic Psychology*. Healy W, Healy MT, trans. Montclair, NJ: Patterson Smith; 1969.

Evidence-Based References

- Modell JG, Mountz JM, Ford CV. Pathological lying associated with thalamic dysfunction demonstrated by [99mTc] HMPAO SPECT. *J Neuropsychiatry Clin Neurosci*. 1992;4:442-446.
- Yang Y, Raine A, Lencz T, et al. Prefrontal white matter in pathological liars. *Br J Psychiatry*. 2005;187:320-325. □

SearchMedica

Do you need to find comprehensive yet focused answers to your psychiatric questions? Why not try SearchMedica? SearchMedica is a search engine specifically designed for psychiatrists and other mental health professionals. The engine breaks down results into easy-to-access categories that include Practical Articles and News, Research Reviews and Editorials, Evidence-based Medicine and Meta-analyses, Practice Guidelines, and Clinical Trials for Patients. Access SearchMedica today by visiting our Web site at www.psychiatristimes.com. □

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.